[WS(P)03] In vivo model and new cancer immunotherapy

[WS03-04-P] Trastuzumab Deruxtecan (T-Dxd), the novel HER2 Antibody-drug-conjugates regulates anti-tumor activity against HER2+ CCA via multiple mechanisms.

^○Prin Sungwan¹, Jutatip Panaampon^1,2, Seiji Okada¹ (1.Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection & Graduate School of Medical Sciences, Kumamoto University, Japan, 2.Division of Hematologic Neoplasia, Dept. of Med. Oncology, Dana-Farber Cancer Inst., Harvard Med. Sch.,450 Brookline Avenue, Boston, Massachusetts (MA), 02215, USA)

キーワード：

immunotherapy、cholangiocarcinoma (CCA)、HER2、Antibody-drug-conjugates

閲覧にはパスワードが必要です

ログイン

または